文献速递免疫规划

呼吸道合胞病毒F亚单位疫苗在健康成人中的安全性和免疫原性:一项1期随机观察者盲法对照剂量递增研究

Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.
PubMed 文献 · Vaccine · 2019-04-12

该研究为首次人体1期观察者盲法试验,纳入18-45岁健康非妊娠女性和男性,按剂量递增分为45µg、90µg、135μg三组,每组内随机接受含铝佐剂、MF59佐剂或无佐剂的RSV F亚单位疫苗两剂或安慰剂。结果显示所有配方耐受良好,无疫苗相关严重不良事件,单剂后中和抗体滴度提升并维持至6个月。

要点

  • 所有配方耐受良好,未报告疫苗相关严重不良事件。
  • 单剂后28天中和抗体GMT升至893-1602,维持高于基线至6个月。
  • 未观察到加强效应,佐剂影响有限。

核心结论

  • 单剂RSV F亚单位疫苗各配方耐受良好,并增强预存中和抗体滴度至6个月随访。

研究设计与样本

  • 首次人体1期观察者盲法对照剂量递增研究(NCT02298179),纳入18-45岁健康非妊娠女性和男性。
  • 参与者按1:1:1逐步剂量递增分入45µg、90µg、135μg三组,每组内按1:1:1:1随机接受含铝佐剂、MF59佐剂或无佐剂疫苗两剂或安慰剂,间隔≥28天。

主要发现

  • 所有配方耐受良好,未报告疫苗相关严重不良事件。
  • 基线时所有参与者抗RSV中和抗体血清阳性,GMT范围为184(95%CI 127-266)至380(95%CI 272-531)。
  • 第一剂后28天,疫苗接种者抗RSV中和抗体GMT范围为893(95%CI 702-1,136)至1,602(95%CI 1,243-2,064)。
  • 未观察到加强效应,但免疫应答在首剂后6个月维持高于接种前水平。
  • 第一剂后28天,RSV F总结合抗体倍数变化与中和抗体倍数变化的比值为2.79至4.12。

临床怎么用

  • 健康成人单剂RSV F亚单位疫苗可增强预存中和抗体并维持至少6个月,支持进一步评估母体免疫策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in infants. An investigational vaccine using an engineered recombinant RSV fusion glycoprotein in its post-fusion conformation (RSV F subunit vaccine) has been developed to protect young infants via maternal immunization. This first-in-human, phase I, observer-blind study (NCT02298179) evaluated the safety and immunogenicity of different dosages and formulations of RSV F subunit vaccine in healthy non-pregnant women and men aged 18-45 years. METHODS: Participants were enrolled (1:1:1) in a stepwise dosage-escalation manner into three cohorts to receive RSV F subunit vaccine containing 45 µg, 90 µg and 135 μg of RSV F glycoprotein. Within each cohort, participants were randomized (1:1:1:1) to receive two doses of RSV F subunit vaccine with (aluminum hydroxide or MF59) or without adjuvant, or placebo, ≥28 days apart. Safety (until day 365 post-dose 2), anti-RSV neutralizing antibodies (NAbs) and serum total binding antibodies to RSV F protein (until day 181 post-dose 1) were evaluated. RESULTS: All formulations were well-tolerated. No vaccine-related serious adverse events were reported. All participants were seropositive for anti-RSV NAbs at baseline, with geometric mean titers (GMTs) ranging from 184 (95% confidence interval [CI]: 127-266) to 380 (95% CI: 272-531). At 28 days post-dose 1, anti-RSV NAb GMTs in vaccine recipients ranged from 893 (95% CI: 702-1,136) to 1,602 (95% CI: 1,243-2,064). No booster effect was observed, but immune responses were maintained above pre-vaccination levels for six months post-dose 1. Ratios of RSV F total binding antibodies fold changes to NAb fold changes ranged from 2.79 to 4.12 at 28 days post-dose 1. The impact of the adjuvant was limited. CONCLUSIONS: A single dose of each formulation of RSV subunit F vaccine was well-tolerated and enhanced preexisting NAb titers through six months of follow-up.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Leroux-Roels G, De Boever F, Maes C, et al. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study. Vaccine. 2019. PMID: 30987852. doi:10.1016/j.vaccine.2019.04.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。